Lisata Therapeutics, INC. (LSTA) — 10-Q Filings

All 10-Q filings from Lisata Therapeutics, INC.. Browse 6 Quarterly Report reports with AI-powered summaries and risk analysis.

10-Q Filings (6)

Lisata Narrows Q3 Loss, Delays Phase 3 Amid Cash Management — Nov 6, 2025 Risk: high
Lisata Therapeutics, Inc. (LSTA) reported a net loss of $4.249 million for the three months ended September 30, 2025, an improvement from the $4.930 million net
10-Q Filing — Aug 7, 2025
Lisata Therapeutics Files Q1 2025 10-Q — May 8, 2025 Risk: medium
Lisata Therapeutics, Inc. filed its 10-Q for the period ending March 31, 2025. The company, formerly known as Caladrius Biosciences, Inc. and NeoStem, Inc., is
Lisata Therapeutics Files Q3 2024 10-Q — Nov 12, 2024 Risk: medium
Lisata Therapeutics, Inc. filed its 10-Q for the period ending September 30, 2024. The company reported financial results and provided updates on its business o
Lisata Therapeutics Files Q2 2024 10-Q — Aug 12, 2024 Risk: medium
Lisata Therapeutics, Inc. filed its 10-Q for the period ending June 30, 2024. The company reported its financial results and provided updates on its business op
Lisata Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024 — May 9, 2024 Risk: low
LISATA THERAPEUTICS, INC. (LSTA) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Lisata Therapeutics, Inc. filed a 10-Q report on May 9, 2024, for

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX